Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ABL
ABL logo

ABL Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
686.91M
Low
--
Amount
--
EV/EBITDA(TTM)
18.14
Total Shares
--
EV
1.16B
EV/OCF(TTM)
--
P/S(TTM)
4.03
Abacus Global Management, Inc. is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company’s segments include Asset Management, Life Solutions and Technology Services. The Asset Management segment provides asset management services to primarily institutional investors alongside private clients investing in uncorrelated and longevity-based assets, fixed-income replacement strategies and free cash flow based investment solutions. It also provides policy servicing activities to customers on a contract basis. The Life Solutions segment is engaged in buying, selling, and trading policies, and maintaining policies until receipt of death benefits. The Technology Services segment provides real-time mortality verification, missing participant verification, and other services specific to the life insurance market services to customers on a contract basis.
Show More

Events Timeline

(ET)
2025-12-19
08:20:00
Abacus Global Management Transfers Listing to NYSE
select
2025-11-06 (ET)
2025-11-06
18:36:00
Abacus Global announces Q3 adjusted EPS of 24 cents, surpassing consensus estimate of 18 cents.
select
2025-11-06
17:51:10
Abacus Global Launches $10 Million Stock Buyback Initiative
select
2025-10-23 (ET)
2025-10-23
08:14:34
Abacus Global offloads $50M in securitized life insurance assets to investors
select
2025-09-22 (ET)
2025-09-22
08:04:22
Abacus Global Added to Russell 2000 and 3000 Indexes
select

News

Yahoo Finance
8.5
04-02Yahoo Finance
PinnedInvestment Opportunities in European Small Caps Amid Market Uncertainty
  • Market Resilience: The STOXX Europe 600 Index has shown a modest gain despite geopolitical tensions and fluctuating energy prices, reflecting cautious optimism that may present potential opportunities for investors in a volatile environment.
  • Small Cap Appeal: Amid economic shifts and sentiment changes, small-cap stocks with active insider participation are emerging as intriguing opportunities for investors seeking undervalued assets, particularly in the current economic landscape.
  • Electrolux Professional Performance: Electrolux Professional, specializing in equipment for laundry and food services, anticipates revenues of SEK 12.2 billion in 2025, and despite a slight sales dip, it projects nearly 19% annual growth, indicating strong potential in a competitive market.
  • Scandi Standard Financial Improvement: Scandi Standard's net income rose from SEK 275 million to SEK 367 million in 2025, and it proposed a dividend of SEK 3.30 per share, demonstrating financial improvement and insider confidence despite high debt levels.
PRnewswire
2.0
01-15PRnewswire
Abacus Global Management Under Investigation for $794 Million Securities Fraud
  • Legal Investigation Launched: The Schall Law Firm has announced an investigation into Abacus Global Management for potential violations of securities laws, involving up to $794 million, which could lead to significant losses for investors.
  • False Statement Allegations: The investigation focuses on whether Abacus issued false or misleading statements and failed to disclose information critical to investors, potentially impacting its stock price and market confidence.
  • Portfolio Valuation Issues: A report by Morpheus Research indicates that Abacus changed its portfolio valuation methodology to appear more profitable than it is, which may mislead investors regarding the company's financial health.
  • Founders' Background Risks: The report also highlights
Businesswire
7.0
01-07Businesswire
Abacus Global Management Faces Investigation Over Alleged Misleading Statements
  • Investigation Launched: The Schall Law Firm is investigating Abacus Global Management for potential violations of securities laws, focusing on whether the company made false or misleading statements that could undermine investor confidence.
  • Financial Transparency Issues: A report by Morpheus Research dated June 4, 2025, claims that Abacus altered its portfolio valuation methodology to appear more profitable than it is, potentially misleading investors about the company's financial health.
  • Controversial Life Expectancy Estimates: The report also alleges that Abacus employs unusual methodologies for calculating life expectancy, raising concerns about the reliability of its financial reporting and possibly inviting further scrutiny from regulators.
  • Founders' Background Risks: The report highlights “red flags” associated with Abacus's co-founders, which could impact corporate governance and investor trust, exacerbating concerns about the company's future performance.
Yahoo Finance
7.5
2025-12-26Yahoo Finance
ABL Bio Secures $55 Million R&D Funding to Accelerate Grabody Platform Expansion
  • Funding Injection: ABL Bio has secured $55 million in R&D funding, including a $40 million upfront payment and a $15 million equity investment, which will significantly accelerate the development of its Grabody platform, particularly in high-unmet-need areas such as obesity and muscle disorders.
  • Collaboration Deepening: ABL Bio is conducting joint research and development on multiple therapeutic candidates with Eli Lilly, planning to leverage the newly secured funding to enhance collaboration and advance its bispecific antibody platform technologies.
  • Clinical Development Expansion: The company intends to use this funding to extend the clinical development of its bispecific immuno-oncology candidates into combination therapies, aiming to improve treatment outcomes and meet market demands.
  • Long-term Strategy: The agreement with Lilly, valued at $2.602 billion, underscores ABL Bio's long-term growth potential in the biopharmaceutical sector and lays the groundwork for future collaborative opportunities.
PRnewswire
7.5
2025-12-26PRnewswire
ABL Bio Secures $55 Million in R&D Funding to Accelerate Grabody Platform Expansion
  • Funding Support: ABL Bio has secured $55 million in R&D funding, including a $40 million upfront payment and a $15 million equity investment, which will significantly accelerate the development of its Grabody platform, particularly in expanding indications for high unmet need areas such as obesity and muscle disorders.
  • Deepening Collaboration: In partnership with Eli Lilly, ABL Bio is conducting joint research on multiple therapeutic candidates, planning to leverage the newly secured funding to enhance collaboration and advance the development of bispecific antibodies and dual payload ADCs.
  • Clinical Development Advancement: ABL Bio is advancing several clinical projects across eight pipelines in the U.S., China, Australia, and Korea, with ABL001 (tovecimig) receiving Fast Track designation from the FDA, indicating strong market potential.
  • Long-term Strategy: By signing a $2.602 billion agreement with Lilly, ABL Bio not only secures immediate funding but also explores extensive collaborative opportunities for future therapy development, thereby enhancing its competitive position in the market.
PRnewswire
3.5
2025-12-26PRnewswire
ABL Bio Secures $55 Million R&D Funding to Accelerate Grabody Platform Expansion
  • Funding Support: ABL Bio has secured $55 million in R&D funding, including a $40 million upfront payment and a $15 million equity investment, significantly enhancing its research capabilities in the bispecific antibody sector.
  • Technology Expansion: The new funding will accelerate R&D on the Grabody platform, particularly expanding into high-unmet-need areas such as obesity and muscle disorders, thereby enhancing the company's competitiveness in the biopharmaceutical market.
  • Deepened Collaboration: ABL Bio's collaboration with Eli Lilly on multiple therapeutic candidates is backed by a licensing agreement valued at $2.602 billion, highlighting the strategic value of their long-term partnership.
  • Clinical Progress: Several clinical projects are underway, including ABL001 (tovecimig), which has received Fast Track designation from the FDA, laying a solid foundation for the company's future market performance.
Wall Street analysts forecast ABL stock price to rise
3 Analyst Rating
Wall Street analysts forecast ABL stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
9.00
Averages
12.17
High
14.00
Current: 0.000
sliders
Low
9.00
Averages
12.17
High
14.00
Piper Sandler
Overweight
maintain
$9 -> $11
AI Analysis
2025-12-23
Reason
Piper Sandler
Price Target
$9 -> $11
AI Analysis
2025-12-23
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Abacus Global to $11 from $9 and keeps an Overweight rating on the shares as part of a Q4 preview for the asset management group. Deal activity has begun to recover, but private credit has dominated headlines as investors worry about a potential surge in defaults, the analyst tells investors in a research note. Piper believes the concerns are overstated, saying fundamentals are "solid" with loan- to-value ratios in the 30%-40% range, "providing substantial cushion against losses."
Piper Sandler
Overweight
downgrade
$12 -> $10
2025-07-02
Reason
Piper Sandler
Price Target
$12 -> $10
2025-07-02
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on Abacus Global to $10 from $12 and keeps an Overweight rating on the shares. The firm notes asset managers have underperformed broader financials and the market year-to-date, but performance has improved in recent months as markets have calmed since the volatility around Liberation Day. In April, sentiment worsened dramatically around tariff announcements with worries deal activity would come to a standstill for months. Since then, there has been some thawing with a return in capital markets activity, Piper adds. In this backdrop, where activity is starting to return but is still far from normal, the firm is favoring credit focused names with management fee focused models.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ABL
Unlock Now

Valuation Metrics

The current forward P/E ratio for Abacus Global Management Inc (ABL.O) is 9.81, compared to its 5-year average forward P/E of 5.72. For a more detailed relative valuation and DCF analysis to assess Abacus Global Management Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
5.72
Current PE
9.81
Overvalued PE
12.99
Undervalued PE
-1.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
4.55
Current EV/EBITDA
9.39
Overvalued EV/EBITDA
9.93
Undervalued EV/EBITDA
-0.82

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.98
Current PS
3.87
Overvalued PS
4.40
Undervalued PS
-0.44

Financials

AI Analysis
Annual
Quarterly

Whales Holding ABL

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Abacus Global Management Inc (ABL) stock price today?

The current price of ABL is 0 USD — it has increased 0

What is Abacus Global Management Inc (ABL)'s business?

Abacus Global Management, Inc. is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company’s segments include Asset Management, Life Solutions and Technology Services. The Asset Management segment provides asset management services to primarily institutional investors alongside private clients investing in uncorrelated and longevity-based assets, fixed-income replacement strategies and free cash flow based investment solutions. It also provides policy servicing activities to customers on a contract basis. The Life Solutions segment is engaged in buying, selling, and trading policies, and maintaining policies until receipt of death benefits. The Technology Services segment provides real-time mortality verification, missing participant verification, and other services specific to the life insurance market services to customers on a contract basis.

What is the price predicton of ABL Stock?

Wall Street analysts forecast ABL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABL is12.17 USD with a low forecast of 9.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Abacus Global Management Inc (ABL)'s revenue for the last quarter?

Abacus Global Management Inc revenue for the last quarter amounts to 62.98M USD, increased 123.72

What is Abacus Global Management Inc (ABL)'s earnings per share (EPS) for the last quarter?

Abacus Global Management Inc. EPS for the last quarter amounts to 0.07 USD, decreased -200.00

How many employees does Abacus Global Management Inc (ABL). have?

Abacus Global Management Inc (ABL) has 157 emplpoyees as of April 03 2026.

What is Abacus Global Management Inc (ABL) market cap?

Today ABL has the market capitalization of 686.91M USD.